Nabriva Hopes To Relaunch Xenleta In Community Setting As Pandemic Subsides

Nabriva Therapeutics plc. is hardly the first antibiotics company to experience a disappointing product launch, but the COVID-19 pandemic presented multiple unexpected challenges in the months after the August 2019 approval of the first-in-class, semi-synthetic pleuromutilin antibiotic Xenleta. The company’s initial hospital-based focus in community-acquired bacterial pneumonia (CABP) has been scrapped for a community health system focus.

During its fourth quarter and full year 2020 earnings call on 11 March, Nabriva reported just $108,000 in 2020 sales...